The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Julia Kirchheiner

Institute of Clinical Pharmacology and the Department of Endocrinology

University Medical Center Charité

Humboldt University

Berlin

Germany

[email]@charite.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Institute of Clinical Pharmacology and the Department of Endocrinology, University Medical Center Charité, Humboldt University, Berlin, Germany. 2002 - 2004
  • Institute of Clinical Pharmacology, Charité, Humboldt University of Berlin, Berlin, Germany. 2003 - 2004

References

  1. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Kirchheiner, J., Meineke, I., Müller, G., Bauer, S., Rohde, W., Meisel, C., Roots, I., Brockmöller, J. Clin. Pharmacokinet (2004) [Pubmed]
  2. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. Kirchheiner, J., Henckel, H.B., Meineke, I., Roots, I., Brockmöller, J. J. Clin. Psychopharmacol (2004) [Pubmed]
  3. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Kirchheiner, J., Meineke, I., Steinbach, N., Meisel, C., Roots, I., Brockmöller, J. Br. J. Clin. Pharmacol (2003) [Pubmed]
  4. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Kirchheiner, J., Kudlicz, D., Meisel, C., Bauer, S., Meineke, I., Roots, I., Brockmöller, J. Clin. Pharmacol. Ther. (2003) [Pubmed]
  5. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Kirchheiner, J., Störmer, E., Meisel, C., Steinbach, N., Roots, I., Brockmöller, J. Pharmacogenetics (2003) [Pubmed]
  6. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Kirchheiner, J., Klein, C., Meineke, I., Sasse, J., Zanger, U.M., Mürdter, T.E., Roots, I., Brockmöller, J. Pharmacogenetics (2003) [Pubmed]
  7. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. Kirchheiner, J., Müller, G., Meineke, I., Wernecke, K.D., Roots, I., Brockmöller, J. J. Clin. Psychopharmacol (2003) [Pubmed]
  8. Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity. Kirchheiner, J., Sasse, J., Meineke, I., Roots, I., Brockmöller, J. Pharmacogenetics (2003) [Pubmed]
  9. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders. Kirchheiner, J., Bertilsson, L., Bruus, H., Wolff, A., Roots, I., Bauer, M. Pharmacopsychiatry (2003) [Pubmed]
  10. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Kirchheiner, J., Brockmöller, J., Meineke, I., Bauer, S., Rohde, W., Meisel, C., Roots, I. Clin. Pharmacol. Ther. (2002) [Pubmed]
  11. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Kirchheiner, J., Meineke, I., Müller, G., Roots, I., Brockmöller, J. Pharmacogenetics (2002) [Pubmed]
 
WikiGenes - Universities